About Ipsen

Facing up to the Future

Innovation. Talent. Focus.

Throughout the world, millions of adults and children are afflicted with endocrine and metabolic diseases that compromise their quality of life. Driven by a passion to help these patients, a group of scientists and clinicians in the fields of endocrinology and growth hormone research came together to establish Tercica in 2002.

 

This founding team shared a single vision: to leverage four decades of collective knowledge into new therapeutic treatments for endocrine and metabolic disorders. Their enthusiasm and talent generated rapid momentum. In 2006, led by its management team, Tercica launched Increlex® (mecasermin [rDNA origin] injection) for the treatment of children with short stature due to Severe Primary IGFD (Insulin-like Growth Factor-1 Deficiency). A few months later, we formed a strategic partnership with Ipsen SA to market Somatuline® Depot (lanreotide) Injection in the United States for the treatment of adults with acromegaly.

 

In July 2007, Tercica and Genentech entered into an agreement for the development, manufacture, and worldwide commercialization of two next-generation growth hormone products. Both products will contain Nutropin AQ® (somatropin [rDNA origin] injection), Genentech's recombinant human growth hormone, in combination with Increlex® (mecasermin [rDNA origin] injection), Tercica's recombinant human insulin-like growth factor-1.

 

In 2008, former strategic partner the Ipsen Group completed its acquisition of Tercica. Tercica is now Ipsen Biopharmaceuticals, Inc., an affiliate of the Ipsen Group.

 

Ipsen is an innovation-driven international specialty pharmaceutical group, currently marketing more than 20 drugs and employing nearly 4,000 people around the world.

 

Our development strategy is based on a combination of specialized products in our targeted therapeutic areas (oncology, endocrinology, and neurology) and primary care products, which help finance our research and development activities.
 

The location of our four Research and Development centers (Paris, Boston, Barcelona, London) and our peptide and protein engineering platform give us a competitive edge in gaining access to leading university research teams and highly qualified personnel.  More than 700 people in R&D are dedicated to the dscovery and development of innovative drugs, which are helping to improve the lives of patients around the world.

 

For more information, please visit the Ipsen Group website.